other material
confidence high
sentiment positive
materiality 0.60
ArriVent BioPharma doses first patient in U.S. Phase 1 trial of ARR-002 for ovarian and endometrial cancer
ArriVent BioPharma, Inc.
- ArriVent (Nasdaq: AVBP) dosed the first patient in the U.S. Phase 1 trial (NCT07755436) of ARR-002, a MUC16/NaPi2b dual-target tetravalent ADC.
- ARR-002 is a potential first-in-class MUC16/NaPi2b dual-target ADC for ovarian and endometrial cancer; both targets are highly over-expressed in these cancers.
- Stuart Lutzker, President of R&D, said ARR-002 is ArriVent's second ADC to enter the clinic, broadening the pipeline beyond lung and gastrointestinal cancers.
- In August 2026, ArriVent licensed ARR-002 from Shanghai Allist Pharmaceuticals for Greater China, including mainland China, Hong Kong, Macau, and Taiwan, retaining all other rights.